Response of thymectomy:: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients

被引:29
作者
Guillermo, GR [1 ]
Téllez-Zenteno, JF [1 ]
Weder-Cisneros, N [1 ]
Mimenza, A [1 ]
Estañol, B [1 ]
Remes-Troche, JM [1 ]
Cantu-Brito, C [1 ]
机构
[1] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Neurol, Mexico City, DF, Mexico
来源
ACTA NEUROLOGICA SCANDINAVICA | 2004年 / 109卷 / 03期
关键词
myasthenia gravis; response; thymectomy; seronegative; seropositive; thymus histology; thymoma;
D O I
10.1034/j.1600-0404.2003.00209.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective - To identify the response to thymectomy in patients with seronegative and seropositive myasthenia gravis (SPMG). We analyzed the associated diseases, thymus histology, and the severity of symptoms between the two groups. Material and methods - Design - Descriptive, comparative. Study units - Fourteen patients with seronegative myasthenia gravis (SNMG) and 57 patients with SPMG who had a thymectomy between 1987 and 1997, with at least 3 years of follow-up. The patients were divided into four groups; (1) Remission, (2) Improvement, (3) No change and (4) Deterioration. Results - Fourteen patients (20%) were seronegative and 57 were seropositive (80%). In the group of patients with SNMG, three patients were in remission (21%), five with improvement (36%), five with no change (36%) and one with worsening (7%). In the group of patients with SPMG, 12 were in remission (21%), 17 with improvement (30%), 25 with no change (44%) and three (5%) with worsening. The patients with SNMG were older, with less associated diseases and with a lower frequency of thymomas. Conclusions - The response to thymectomy was similar between the two groups. It has been suggested that seronegative patients have a better prognosis, but our results show no differences.
引用
收藏
页码:217 / 221
页数:5
相关论文
共 26 条
[1]   ACETYLCHOLINE-RECEPTOR ANTIBODIES IN JUVENILE MYASTHENIA-GRAVIS [J].
ANDREWS, PI ;
MASSEY, JM ;
SANDERS, DB .
NEUROLOGY, 1993, 43 (05) :977-982
[2]   ANTI-ACHR ANTIBODIES, THYMIC HISTOLOGY, AND T-CELL SUBSETS IN MYASTHENIA-GRAVIS [J].
BERRIH, S ;
MOREL, E ;
GAUD, C ;
RAIMOND, F ;
LEBRIGAND, H ;
BACH, JF .
NEUROLOGY, 1984, 34 (01) :66-71
[3]   MYASTHENIA-GRAVIS - LONG-TERM CORRELATION OF BINDING AND BUNGAROTOXIN BLOCKING ANTIBODIES AGAINST ACETYLCHOLINE-RECEPTORS WITH CHANGES IN DISEASE SEVERITY [J].
BESINGER, UA ;
TOYKA, KV ;
HOMBERG, M ;
HEININGER, K ;
HOHLFELD, R ;
FATEHMOGHADAM, A .
NEUROLOGY, 1983, 33 (10) :1316-1321
[4]   Myasthenia gravis and tumours of the thymic region - Report of a case in which the tumor was removed [J].
Blalock, A ;
Mason, MF ;
Morgan, HJ ;
Riven, SS .
ANNALS OF SURGERY, 1939, 110 :544-561
[5]   Long-term outcome and quality of life after thymectomy for myasthenia gravis [J].
Busch, C ;
Machens, A ;
Pichlmeier, U ;
Emskotter, T ;
Izbicki, JR .
ANNALS OF SURGERY, 1996, 224 (02) :225-232
[6]   MEDICAL PROGRESS - MYASTHENIA-GRAVIS [J].
DRACHMAN, DB .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (25) :1797-1810
[7]  
EVOLI A, 1989, CLIN INVEST MED, V12, P104
[8]  
Frist W., 1991, J NEUROL NEUROSUR PS, V54, P406
[9]   Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review) - Report of the Quality Standards Subcommittee of the American Academy of Neurology [J].
Gronseth, GS ;
Barohn, RJ .
NEUROLOGY, 2000, 55 (01) :7-15
[10]   THYMECTOMY FOR MYASTHENIA-GRAVIS - 14-YEAR EXPERIENCE [J].
HANKINS, JR ;
MAYER, RF ;
SATTERFIELD, JR ;
TURNEY, SZ ;
ATTAR, S ;
SEQUEIRA, AJ ;
THOMPSON, BW ;
MCLAUGHLIN, JS .
ANNALS OF SURGERY, 1985, 201 (05) :618-625